# Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

> **NCT00457119** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 69 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00457119
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2013-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457119, "Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00457119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*